These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21887501)

  • 21. A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
    Sakiyama T; Tsurutani J; Iwasa T; Kawakami H; Nonagase Y; Yoshida T; Tanaka K; Fujisaka Y; Kurata T; Komoike Y; Nishio K; Nakagawa K
    Br J Cancer; 2015 Mar; 112(5):819-24. PubMed ID: 25654665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.
    Arnold SM; Moon J; Williamson SK; Atkins JN; Ou SH; LeBlanc M; Urba SG
    Invest New Drugs; 2011 Apr; 29(2):352-9. PubMed ID: 19937365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
    Devriese LA; Witteveen PE; Wanders J; Law K; Edwards G; Reyderman L; Copalu W; Peng F; Marchetti S; Beijnen JH; Huitema AD; Voest EE; Schellens JH
    Br J Clin Pharmacol; 2013 Feb; 75(2):507-15. PubMed ID: 22803519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
    Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
    Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Mok TS; Geater SL; Iannotti N; Thongprasert S; Spira A; Smith D; Lee V; Lim WT; Reyderman L; Wang B; Gopalakrishna P; Garzon F; Xu L; Reynolds C
    Ann Oncol; 2014 Aug; 25(8):1578-84. PubMed ID: 24827127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in therapy: eribulin improves survival for metastatic breast cancer.
    Morris PG
    Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
    Reda M; Macaire P; Bellio H; Uwer L; Ilie S; Lorgis V; Hennequin A; Ladoire S; Rederstorff E; Fumoleau P; Isambert N; Bonnin N; You B; Freyer G; Desmoulins I; Schmitt A
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):197-208. PubMed ID: 34997290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
    Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
    Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eribulin mesylate for the treatment of late-stage breast cancer.
    Gourmelon C; Frenel JS; Campone M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
    Roviello G; Milani M; Gobbi A; Cappelletti MR; Zanotti L; Senti C; Bottini A; Strina C; Sigala S; Generali D
    Clin Breast Cancer; 2016 Jun; 16(3):e57-9. PubMed ID: 26943987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
    Devriese LA; Mergui-Roelvink M; Wanders J; Jenner A; Edwards G; Reyderman L; Copalu W; Peng F; Marchetti S; Beijnen JH; Schellens JH
    Invest New Drugs; 2013 Apr; 31(2):381-9. PubMed ID: 22555773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.
    Goodin S; Barbour S; Song J; Berrak E; Cox D
    Am J Health Syst Pharm; 2015 Dec; 72(24):2150-6. PubMed ID: 26637514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eribulin: a novel cytotoxic chemotherapy agent.
    Preston JN; Trivedi MV
    Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.
    Renouf DJ; Tang PA; Major P; Krzyzanowska MK; Dhesy-Thind B; Goffin JR; Hedley D; Wang L; Doyle L; Moore MJ
    Invest New Drugs; 2012 Jun; 30(3):1203-7. PubMed ID: 21526355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
    Spira AI; Iannotti NO; Savin MA; Neubauer M; Gabrail NY; Yanagihara RH; Zang EA; Cole PE; Shuster D; Das A
    Clin Lung Cancer; 2012 Jan; 13(1):31-8. PubMed ID: 21862415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.
    Goel S; Swami U; Kumar K; Dittrich C; Reyderman L; Jain M; Aisner J; Song J; Petrylak DP
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):567-578. PubMed ID: 31190276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eribulin mesylate.
    Jain S; Vahdat LT
    Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
    Marmé F; Gomez-Roca C; Graudenz K; Huang F; Lettieri J; Peña C; Trnkova ZJ; Eucker J
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):727-737. PubMed ID: 29468456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.